Better prognostic markers for nonmuscle invasive papillary urothelial carcinomas

Bladder cancer is a common type of cancer, especially among men in developed countries. Most cancers in the urinary bladder are papillary urothelial carcinomas. They are characterized by a high recurrence frequency (up to 70 %) after local resection. It is crucial for prognosis to discover these recurrent tumours at an early stage, especially before they become muscle-invasive. Reliable prognostic biomarkers for tumour recurrence and stage progression are lacking. This is why patients diagnosed with a non-muscle invasive bladder cancer follow extensive follow-up regimens with possible serious side effects and with high costs for the healthcare systems. WHO grade and tumour stage are two central biomarkers currently having great impact on both treatment decisions and follow-up regimens. However, there are concerns regarding the reproducibility of WHO grading, and stage classification is challenging in small and fragmented tumour material. In Paper I, we examined the reproducibility and the prognostic value of all the individual microscopic features making up the WHO grading system. Among thirteen extracted features there was considerable variation in both reproducibility and prognostic value. The only feature being both reasonably reproducible and statistically significant prognostic was cell polarity. We concluded that further validation studies are needed on these features, and that future grading systems should be based on well-defined features with true prognostic value. With the implementation of immunotherapy, there is increasing interest in tumour immune response and the tumour microenvironment. In a search for better prognostic biomarkers for tumour recurrence and stage progression, in Paper II, we investigated the prognostic value of tumour infiltrating immune cells (CD4, CD8, CD25 and CD138) and previously investigated cell proliferation markers (Ki-67, PPH3 and MAI). Low Ki 67 and tumour multifocality were associated with increased recurrence risk. Recurrence risk was not affected by the composition of immune cells. For stage progression, the only prognostic immune cell marker was CD25. High values for MAI was also strongly associated with stage progression. However, in a multivariate analysis, the most prognostic feature was a combination of MAI and CD25. BCG-instillations in the bladder are indicated in intermediate and high-risk non-muscle invasive bladder cancer patients. This old-fashion immunotherapy has proved to reduce both recurrence- and progression-risk, although it is frequently followed by unpleasant side-effects. As many as 30-50% of high-risk patients receiving BCG instillations, fail by develop high-grade recurrences. They do not only suffer from unnecessary side-effects, but will also have a delay in further treatment. Together with colleagues at three different Dutch hospitals, in Paper III, we looked at the prognostic and predictive value of T1-substaging. A T1-tumour invades the lamina propria, and we wanted to separate those with micro- from those with extensive invasion. We found that BCG-failure was more common among patients with extensive invasion. Furthermore, T1-substaging was associated with both high-grade recurrence-free and progression-free survival. Finally, in Paper IV, we wanted to investigate the prognostic value of two classical immunohistochemical markers, p53 and CK20, and compare them with previously investigated proliferation markers. p53 is a surrogate marker for mutations in the gene TP53, considered to be a main characteristic for muscle-invasive tumours. CK20 is a surrogate marker for luminal tumours in the molecular classification of bladder cancer, and is frequently used to distinguish reactive urothelial changes from urothelial carcinoma in situ. We found both positivity for p53 and CK20 to be significantly associated with stage progression, although not performing better than WHO grade and stage. The proliferation marker MAI, had the highest prognostic value in our study. Any combination of variables did not perform better in a multivariate analysis than MAI alone

Towards an Effective Imaging-Based Decision Support System for Skin Cancer

The usage of expert systems to aid in medical decisions has been employed since 1980s in distinct ap plications. With the high demands of medical care and limited human resources, these technologies are required more than ever. Skin cancer has been one of the pathologies with higher growth, which suf fers from lack of dermatology experts in most of the affected geographical areas. A permanent record of examination that can be further analyzed are medical imaging modalities. Most of these modalities were also assessed along with machine learning classification methods. It is the aim of this research to provide background information about skin cancer types, medical imaging modalities, data mining and machine learning methods, and their application on skin cancer imaging, as well as the disclosure of a proposal of a multi-imaging modality decision support system for skin cancer diagnosis and treatment assessment based in the most recent available technology. This is expected to be a reference for further implementation of imaging-based clinical support systems.info:eu-repo/semantics/publishedVersio

Automated tumour budding quantification by machine learning augments TNM staging in muscle-invasive bladder cancer prognosis

Tumour budding has been described as an independent prognostic feature in several tumour types. We report for the first time the relationship between tumour budding and survival evaluated in patients with muscle invasive bladder cancer. A machine learning-based methodology was applied to accurately quantify tumour buds across immunofluorescence labelled whole slide images from 100 muscle invasive bladder cancer patients. Furthermore, tumour budding was found to be correlated to TNM (p = 0.00089) and pT (p = 0.0078) staging. A novel classification and regression tree model was constructed to stratify all stage II, III, and IV patients into three new staging criteria based on disease specific survival. For the stratification of non-metastatic patients into high or low risk of disease specific death, our decision tree model reported that tumour budding was the most significant feature (HR = 2.59, p = 0.0091), and no clinical feature was utilised to categorise these patients. Our findings demonstrate that tumour budding, quantified using automated image analysis provides prognostic value for muscle invasive bladder cancer patients and a better model fit than TNM staging.Publisher PDFPeer reviewe

Risk factors and biomarkers for metastatic cutaneous squamous cell carcinoma

The incidence of cutaneous squamous cell carcinoma (cSCC), the most common skin cancer with metastatic potential, continues to increase. Although proportion of cSCCs metastasize and cause mortality, sufficient means to identify the metastasis-prone tumors are not available. In this thesis the metastatic cSCCs from the area served by Turku University Hospital were identified and characterized revealing that the rate of metastasis in the study region was 2.3%. Further, it was discovered that metastasis occurs rapidly and that there was no history of cSCC in 85% of patients with metastatic cSCC. Invasion depth, tumor diameter, age and location on lower lip or forehead were associated with increased risk of metastasis. On the other hand, usage of isosorbide mono-/dinitrate and aspirin as well as comorbidity with premalignant lesions or basal cell carcinoma were associated with lower risk of metastasis. With multiplexed immunohistochemistry, it was demonstrated that the activity and phenotype of cancer-associated fibroblasts (CAFs) evolve during the progression of cSCC. Elevation of α-smooth muscle actin (αSMA), secreted protein acidic and rich in cysteine (SPARC) and fibroblast activating protein (FAP) expression was associated with invasion and expression of FAP and platelet-derived growth factor receptor-β (PDGFRβ) with metastasis. High expression of stromal PDGFRβ and periostin were associated with worse prognosis. CAF107 (PDGFRα-/PDGFRβ+/FAP+) subset was associated with invasion and metastasis, and predicted poor prognosis of cSCC. A deep learning algorithm was harnessed to distinguish primary tumors that metastasize rapidly from non-metastatic cSCCs with slide level area under the receiver operating characteristic curve (AUROC) of 0.747 on whole slide images representing primary cSCCs. Furthermore, a risk factor model, that utilized prediction by AI, was created and provided staging systems and comparative risk factor models surpassing classification and prognostivity. These results characterize features associated with the metastasis risk of cSCC and indicate that CAF-markers and AI could provide clinical tools for the metastasis risk assessment and thus improve the prognosis of patient with metastatic cSCC.Etäpesäkkeitä lähettävän okasolusyövän riskitekijät ja biomarkkerit Yleisimmän etäpesäkkeitä lähettävän ihosyövän, okasolusyövän, ilmaantuvuus jatkaa kasvuaan. Vaikka osa okasolusyövistä lähettää etäpesäkkeitä ja aiheuttaa kuolleisuutta, ei etäpesäkkeitä lähettämään tulevien okasolusyöpien tunnistamiseksi ole toistaiseksi riittäviä keinoja. Tässä väitöskirjassa karakterisoitiin Turun yliopistollisen keskussairaalan vastuualueen metastasoituneet okasolusyövät ja osoitettiin että tutkimusalueen okasolusyövistä 2.3% etenee etäpesäkkeitä lähettäväksi. Metastasoituminen tapahtui nopeasti ja valtaosassa tapauksista (85%) etäpesäkkeen lähetti ensimmäinen potilaalla todettu okasolusyöpä. Ikä, kasvaimen invaasiosyvyys, halkaisija ja sijainti alahuulessa tai otsalla yhdistyivät kohonneeseen metastaasiriskiin. Isosorbidinitraatin ja aspiriinin käyttö sekä esiasteiden ja tyvisolusyövän esiintyminen taas liittyivät alentuneeseen metastaasiriskiin. Multiplex-immunohistokemiaa hyödyntäen osoitettin, että syöpään liittyvien fibroblastien (CAF) aktiviteetti ja ilmiasu muuttuu okasolusyövän edetessä. Kohonnut sileälihasaktiini alfan (αSMA), osteonektiinin ja fibroblastia aktivoivan proteiinin (FAP) ilmentyminen liittyi invaasioon ja FAP:n sekä verihiutaleista johdetun kasvutekijäreseptori β:n (PDGFRβ) etäpesäkkeiden lähettämiseen. PDGFRβ:n ja periostiinin ilmentyminen taas yhdistyi huonoon ennusteeseen. CAF107 (PDGFRα-/PDGFRβ+/FAP+) alatyyppi liittyi invaasioon, metastasointiin ja huonoon ennusteeeseen. Etäpesäkkeitä lähettämään tulevien okasolusyöpien tunnistamiseen valjastettu syväoppimisalgoritmi erotti okasolusyöpiä edustavista digitalisoiduista mikroskopiakuvista nopeasti etäpesäkkeitä lähettävät okasolusyövät okasolusyövistä, jotka eivät lähetä etäpesäkkeitä, leiketason AUROC-arvolla 0.747. Tekoälyarviota hyödyntävä riskitekijämalli voitti luokittelujärjestelmät ja kilpailevat riskitekijämallit okasolusyöpien luokittelussa ja ennusteen arvioinnissa. Tulokset antavat lisätietoa metastasoituvan okasolusyövän luonteesta ja osoittavat CAF-markkereiden sekä tekoälyn voivan tarjota kliinisiä työkaluja okasolusyövän metastaasiriskin arviointiin ja täten voivan parantaa etäpesäkkeitä lähettävän okasolusyöpäpotilaan ennustetta tulevaisuudessa